Authors : Nshimirimana Jonas; Josephine W. Kimani; James Kimotho; Matthew Mutinda Munyao; Samson Muuo Nzou

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/yc3dhmsa

Scribd : https://tinyurl.com/mukbka8c

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY1831

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : The onset of Coronavirus disease 2019 (COVID-19) in late 2019 presented a severe worldwide health crisis with widespread morbidity and mortality. Various vaccine platforms have been rapidly developed and approved for broad use in a swift and urgent response to prevent the transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. However, these vaccines differ significantly in terms of safety. Heterologous prime-boost vaccination enhances vaccine safety compared to homologous vaccination, although it could lead to a higher cumulative number of transient adverse events reported at each visit. Therefore, additional strategies are necessary to improve SARS- CoV-2 vaccine safety. Anecdotal options suggest that vaccine co-administration can significantly reduce these adverse effects and consequently, avert the need for frequent booster doses. This study reports the immunization outcomes against the SARS-CoV-2 virus by assessing the safety profiles of different SARS-CoV-2 vaccines co-administered in BALB/c mice. Vaccine combinations comprising mRNA/adenovirus26-vector, mRNA/inactivated, adenovirus26-vector/inactivated, and mRNA/adenovirus26-vector/inactivated vaccines were prepared in optimized doses, and their activities upon immunization evaluated in comparison with individual mRNA, adenovirus26-vectored and inactivated vaccines. Twenty-eight days post-immunization, safety profiles of the various treatments were evaluated through hematological and biochemical examination. Importantly, the co-administration regimens proved safe and were well-tolerated in mice, as evidenced by the normal hematological and biochemical values.

Keywords : mRNA Vaccine; Adenovirus26 Vector Vaccine; Inactivated Vaccine; SARS-Cov-2; Co-Administration; Safety; BALB/C Mice.

References :

1. K. Dhama et al., ‘Coronavirus Disease 2019–COVID-19’, Clin Microbiol Rev, vol. 33, no. 4, Sep. 2020, doi: 10.1128/CMR.00028-20.
2. Chang, X. Chang, Y. He, and K. J. K. Tan, ‘The determinants of COVID-19 morbidity and mortality across countries’, Sci Rep, vol. 12, no. 1, Dec. 2022, doi: 10.1038/s41598-022-09783-9.
3. Richards et al., ‘Economic Burden of COVID-19: A Systematic Review’, ClinicoEconomics and Outcomes Research, vol. 14. Dove Medical Press Ltd, pp. 293–307, 2022. doi: 10.2147/CEOR.S338225.
4. WHO, ‘WHO Coronavirus (COVID-19) Dashboard’, Geneva: World Health Organization, 2023, Accessed: Nov. 11, 2023. [Online]. Available: https://covid19.who.int/
5. Haque and A. B. Pant, ‘Efforts at COVID-19 Vaccine Development: Challenges and Successes’, Vaccines (Basel), vol. 8, no. 4, p. 739, Dec. 2020, doi: 10.3390/vaccines8040739.
6. H. Barouch, ‘Covid-19 Vaccines — Immunity, Variants, Boosters’, New England Journal of Medicine, vol. 387, no. 11, pp. 1011–1020, Sep. 2022, doi: 10.1056/nejmra2206573.
7. Mevorach et al., ‘Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel’, New England Journal of Medicine, vol. 385, no. 23, pp. 2140–2149, Dec. 2021, doi: 10.1056/NEJMoa2109730.
8. M. E. Oster et al., ‘Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021’, JAMA, vol. 327, no. 4, p. 331, Jan. 2022, doi: 10.1001/jama.2021.24110.
9. K. E. Hanson et al., ‘Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink’, JAMA Netw Open, vol. 5, no. 4, p. e228879, Apr. 2022, doi: 10.1001/jamanetworkopen.2022.8879.
10. M. Sarkar, I. Madabhavi, P. Quy, and M. Govindagoudar, ‘COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review’, Ann Thorac Med, vol. 17, no. 1, p. 1, 2022, doi: 10.4103/atm.atm_404_21.
11. R. Rashedi, N. Samieefar, N. Masoumi, S. Mohseni, and N. Rezaei, ‘COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts’, J Med Virol, vol. 94, no. 4, pp. 1294–1299, Apr. 2022, doi: 10.1002/jmv.27463.
12. R. L. Atmar et al., ‘Homologous and Heterologous Covid-19 Booster Vaccinations’, New England Journal of Medicine, vol. 386, no. 11, pp. 1046–1057, Mar. 2022, doi: 10.1056/NEJMoa2116414.
13. S. Kanokudom et al., ‘Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine’, Vaccines (Basel), vol. 10, no. 1, p. 86, Jan. 2022, doi: 10.3390/vaccines10010086.
14. P. Bonanni et al., ‘Vaccine co-administration in adults: An effective way to improve vaccination coverage’, Hum Vaccin Immunother, vol. 19, no. 1, Jan. 2023, doi: 10.1080/21645515.2023.2195786.
15. P. Rzymski et al., ‘COVID-19 vaccine boosters: The good, the bad, and the ugly’, Vaccines (Basel), vol. 9, no. 11, Nov. 2021, doi: 10.3390/vaccines9111299.
16. J. S. Woodworth et al., ‘A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin’, Nat Commun, vol. 12, no. 1, p. 6658, Nov. 2021, doi: 10.1038/s41467-021-26934-0.
17. C. Sing et al., ‘COVID ‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study’, Am J Hematol, vol. 97, no. 4, pp. 470–480, Apr. 2022, doi: 10.1002/ajh.26478.
18. P. S, R. R, and K. R, ‘Blood sample collection in small laboratory animals’, J Pharmacol Pharmacother, vol. 1, no. 2, pp. 87–93, Dec. 2010, doi: 10.4103/0976-500X.72350.
19. Wang et al., ‘Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2’, Cell, vol. 182, no. 3, pp. 713-721.e9, Aug. 2020, doi: 10.1016/j.cell.2020.06.008.
20. W. Santos et al., ‘Hematological and biochemical reference values for C57BL/6, Swiss Webster and BALB/c mice’, Braz J Vet Res Anim Sci, vol. 53, no. 2, p. 138, Jun. 2016, doi: 10.11606/issn.1678-4456.v53i2p138-145.
21. Silva‐Santana et al., ‘Clinical hematological and biochemical parameters in Swiss, BALB/c, C57BL/6 and B6D2F1 Mus musculus’, Animal Model Exp Med, vol. 3, no. 4, pp. 304–315, Dec. 2020, doi: 10.1002/ame2.12139.
22. Gomez-Rial, I. Rivero-Calle, A. Salas, and F. Martinon-Torres, ‘

    Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

    ’, Infect Drug Resist, vol. Volume 13, pp. 2485–2493, Jul. 2020, doi: 10.2147/IDR.S258639.
23. C. Shi and E. G. Pamer, ‘Monocyte recruitment during infection and inflammation’, Nat Rev Immunol, vol. 11, no. 11, pp. 762–774, Nov. 2011, doi: 10.1038/nri3070.
24. G. Silva‐Santana et al., ‘Clinical hematological and biochemical parameters in Swiss, BALB/c, C57BL/6 and B6D2F1 Mus musculus’, Animal Model Exp Med, vol. 3, no. 4, pp. 304–315, Dec. 2020, doi: 10.1002/ame2.12139.
25. J. Gomez-Rial, I. Rivero-Calle, A. Salas, and F. Martinon-Torres, ‘

    Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

    ’, Infect Drug Resist, vol. Volume 13, pp. 2485–2493, Jul. 2020, doi: 10.2147/IDR.S258639.
26. C. Shi and E. G. Pamer, ‘Monocyte recruitment during infection and inflammation’, Nat Rev Immunol, vol. 11, no. 11, pp. 762–774, Nov. 2011, doi: 10.1038/nri3070.
27. J. Liu et al., ‘Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines’, Cell Discov, vol. 7, no. 1, p. 99, Oct. 2021, doi: 10.1038/s41421-021-00329-3.
28. M. J. Cascio and T. G. DeLoughery, ‘Anemia’, Medical Clinics of North America, vol. 101, no. 2, pp. 263–284, Mar. 2017, doi: 10.1016/j.mcna.2016.09.003.
29. M. Izak and J. B. Bussel, ‘Management of thrombocytopenia’, F1000Prime Rep, vol. 6, Jun. 2014, doi: 10.12703/P6-45.
30. D. Al‐Ali et al., ‘Cardiovascular and haematological events post COVID‐19 vaccination: A systematic review’, J Cell Mol Med, vol. 26, no. 3, pp. 636–653, Feb. 2022, doi: 10.1111/jcmm.17137.
31. H. Akiyama et al., ‘Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine’, IDCases, vol. 25, p. e01245, 2021, doi: 10.1016/j.idcr.2021.e01245.
32. T. Iba and J. H. Levy, ‘Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination’, Trends Cardiovasc Med, vol. 32, no. 5, pp. 249–256, Jul. 2022, doi: 10.1016/j.tcm.2022.02.008.
33. S. R. Ostrowski et al., ‘Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis’, Front Immunol, vol. 12, Nov. 2021, doi: 10.3389/fimmu.2021.779453.
34. P. Rzymski, B. Perek, and R. Flisiak, ‘Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism’, Vaccines (Basel), vol. 9, no. 6, p. 559, May 2021, doi: 10.3390/vaccines9060559.
35. E. J. Woo et al., ‘Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990–2008’, Vaccine, vol. 29, no. 6, pp. 1319–1323, Feb. 2011, doi: 10.1016/j.vaccine.2010.11.051.
36. M. E. Mingot-Castellano et al., ‘COVID-19 Vaccines and Autoimmune Hematologic Disorders’, Vaccines (Basel), vol. 10, no. 6, p. 961, Jun. 2022, doi: 10.3390/vaccines10060961.
37. T. A. Woreta and S. A. Alqahtani, ‘Evaluation of Abnormal Liver Tests’, Medical Clinics of North America, vol. 98, no. 1, pp. 1–16, Jan. 2014, doi: 10.1016/j.mcna.2013.09.005.